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Abstract
Epithelial to mesenchymal transition (EMT) is a dynamic process that drives cancer cell plasticity and is thought to play a
major role in metastasis. Here we show, using MDA-MB-231 cells as a model, that the plasticity of at least some metastatic
breast cancer cells is dependent on the transcriptional co-regulator CBFβ. We demonstrate that CBFβ is essential to maintain
the mesenchymal phenotype of triple-negative breast cancer cells and that CBFβ-depleted cells undergo a mesenchymal to
epithelial transition (MET) and re-organise into acini-like structures, reminiscent of those formed by epithelial breast cells.
We subsequently show, using an inducible CBFβ system, that the MET can be reversed, thus demonstrating the plasticity of
CBFβ-mediated EMT. Moreover, the MET can be reversed by expression of the EMT transcription factor Slug whose
expression is dependent on CBFβ. Finally, we demonstrate that loss of CBFβ inhibits the ability of metastatic breast cancer
cells to invade bone cell cultures and suppresses their ability to form bone metastases in vivo. Together our findings
demonstrate that CBFβ can determine the plasticity of the metastatic cancer cell phenotype, suggesting that its regulation in
different micro-environments may play a key role in the establishment of metastatic tumours.
Introduction
The triple-negative sub-type of breast cancer is a highly
aggressive cancer for which treatment options are limited
[1]. Expression of the RUNX transcription factors in
patients with the triple-negative sub-type of breast cancer
correlates with a poor prognosis [2, 3]. Emerging evidence
suggests that the role of RUNX proteins in breast cancer is
dependent on the specific RUNX factor involved and the
sub-type of breast cancer cell [4]. In order to consider the
RUNX factors as viable targets in breast cancer therapies it
is therefore critically important to determine the role of the
different factors in different sub-types of breast cancer.
Since CBFβ facilitates the function of all three RUNX
transcription factors, establishing its role in determining the
phenotype of breast cancer cells is essential [5, 6].
Mutations in CBFβ are amongst the most frequently
reported for breast cancer tumours, suggesting a tumour
suppressor role for CBFβ in ER+ breast cancer [7, 8]. In
contrast, we and others have previously shown that
expression of RUNX2 and CBFβ contribute to the meta-
static phenotype of triple-negative breast cancer cells [9–
12]. In this context it is therefore the maintained expression
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of RUNX factor activity that promotes their metastatic
phenotype.
Epithelial to mesenchymal transition (EMT) contributes
to the progression of metastatic cancer as it enables cancer
cells to become migratory and invasive [13–15]. EMT is
also a plastic programme in which cells dynamically tran-
sition along a continuum of states between epithelial and
mesenchymal phenotypes [16, 17]. This plasticity is thought
to enable mesenchymal cancer cells to switch from a
migratory to an epithelial phenotype during colonization of
the metastatic niche. Previous studies have shown that
RUNX factors have different roles in EMT in different
breast cell-types [18–21]. In ER-negative MCF10A cells,
expression of RUNX1 suppresses EMT, whereas
RUNX2 stimulates an EMT-like phenotype in these cells. In
triple-negative MDA-MB-231 cells, depletion of RUNX2
inhibited their invasive capacity, consistent with suppres-
sion of EMT [22].
Since CBFβ forms functional complexes with all RUNX
transcription factors, it is essential to establish its role in
breast cancer metastasis. Here we show that CBFβ-depleted
triple-negative cells were able to undergo a reversion from a
mesenchymal phenotype to an epithelial phenotype. Indeed,
acini-like structures with clear lumen were observed,
reminiscent of those formed by normal epithelial breast
cells. Remarkably, re-induction of CBFβ, using an inducible
system, led to a complete reversion from the epithelial
phenotype to a mesenchymal phenotype, demonstrating the
plasticity of CBFβ-driven EMT. We subsequently show that
CBFβ maintains the mesenchymal phenotype through acti-
vation of the EMT transcription factor Slug. We also show
that the maintenance of the mesenchymal phenotype is
dependent upon CBFβ and RUNX2, as depletion of either
of these factors resulted in MET. Finally, we demonstrate
that loss of CBFβ, inhibits the ability of metastatic breast
cancer cells to colonise osteoblasts in long-term 3D cul-
tures. Together our findings demonstrate that the CBFβ
complexes can determine the plasticity of the metastatic
cancer cell phenotype, suggesting that their regulation in
different micro-environments may play a key role in the
establishment of metastatic tumours.
Results
CBFβ maintains the mesenchymal phenotype of
MDA-MB-231 cells
We have previously shown that depletion of CBFβ in
metastatic MDA-MB-231 breast cancer cells inhibits their
ability to migrate [11]. This is not restricted to MDA-MB-
231 cells as knockdown of CBFβ in the MDA-MB-468
metastatic cell line also inhibited their migration (Fig. S2).
We also observed that CBFβ-depleted cells exhibit a more
rounded phenotype and were unable to migrate in a wound-
healing assay (Fig. 1a). These observations suggested that
the cells had undergone a profound phenotypic change.
When grown in 3D culture, normal mammary epithelial
cells differentiate into organised acini structures with clearly
identifiable lumen, reminiscent of normal mammary gland
morphology, whereas metastatic cells exhibit a mesenchy-
mal phenotype and form a stellate appearance. We therefore
compared the 3D morphology of wild-type metastatic breast
cancer cells, MDA-MB-231, with MDA-MB-231 cells
depleted of CBFβ. As expected, when grown in 3D, MDA-
MB-231 cells spread throughout the culture, displaying a
typical stellate pattern that reflects their mesenchymal
phenotype (Fig.1b) [23]. In contrast, depletion of CBFβ
resulted in a striking loss of the stellate pattern and the
formation of clusters and spherical colonies (Fig. 1b).
We next used confocal microscopy to determine the
extent to which the cells had differentiated in the absence of
CBFβ (Fig. 1c, d). Remarkably, a small number of these
structures contained clearly identifiable lumen reminiscent
of acini typically formed by mammary epithelial cells (Fig.
1c–e), whilst the larger clusters did not appear to contain
lumen (Fig. 1d, lower panels). Subsequent immuno-
fluorescence staining demonstrated that some of these
structures were also polarised and expressed the basement
membrane markers integrins α6 and β4 on the apical surface
and phospho-ezrin-radixin-moesin (pERM) on the luminal
surface, as found in wild-type acini structures (Fig. 1e) [24].
These observations suggested that the cells had actually
undergone a mesenchymal to epithelial transition (MET).
To confirm this, we used RT-PCR to determine the
expression of a number of mesenchymal and epithelial
markers in wild-type MDA-MB-231 cells and the MDA-
shCBFβ cells. Of the eight mesenchymal markers analysed,
seven had significantly reduced expression in the MDA-
shCBFβ cells. This reduction in mesenchymal markers was
accompanied by an increase in expression of the four epi-
thelial markers analysed (Fig. 1f).
Another feature of EMT is that it leads to an increase in
the number of cancer stem cells (CSCs) [17]. The potential
for stem cell formation can be monitored using the mam-
mosphere assay [25]. We therefore examined the number of
mammospheres formed in the presence and absence of
CBFβ. Loss of CBFβ resulted in a significant reduction in
the number of mammospheres formed when compared to
parental MDA-MB-231 cells, suggesting that in the absence
of CBFβ the potential to produce CSCs is reduced (Fig. 1g).
Taken together, our data demonstrate that CBFβ is essential
for the maintenance of the mesenchymal phenotype in
MDA-MB-231 cells and suggests that loss of CBFβ
expression causes differentiation towards a more epithelial-
like phenotype.
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Examination of EMT marker expression in MDA-MB-
468 cells in the absence of CBFβ showed that the
mesenchymal markers SNAI2 and OPN increased sig-
nificantly, with little change in other mesenchymal markers,
including MMP9, SNAI1 and Vimentin. MMP13 was the
only mesenchymal marker examined that displayed a
reduction in expression. Expression of the epithelial mar-
kers cytokeratin-7, desmoplakin and E-cadherin did not
change either. These data show that CBFβ is required to
maintain the invasive capacity of MDA-MB-468 cells but
its loss does not result in a complete MET, as determine by
the limited changes in classical EMT marker gene expres-
sion. When compared with MDA-MB-231 cells these
findings suggest that both cell-types require CBFβ for
invasion but that it is likely that RUNX complexes regulate
different gene expression programmes dependent on the
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specific cellular context. Our subsequent analysis therefore
focussed on the role of CBFβ and RUNX transcription
factors in EMT/MET transition in MDA-MB-231 cells.
CBFβ regulates EMT/MET state-transition
Dynamic EMT/MET state-transition is thought to enable
metastatic cancer cells to switch between the two pheno-
types, a property that allows them to both invade and
colonise other tissues [17, 26]. We therefore sought to
establish if the dynamic EMT/MET state-transition could be
regulated by the expression of CBFβ. To do this we created
a cell line in which the activity of CBFβ can be regulated by
the addition of 4-Hydroxytamoxifen (4OH-T) (Fig. 2a) [27].
MDA-shCBFβ cells stably expressing a CBFβ-ER fusion
protein were generated and western blotting confirmed that
the addition of 4OH-T to these cells induced nuclear
expression of CBFβ-ER (Fig. 2a). RT-PCR analysis showed
that there was also a concomitant increase in expression of
the known RUNX-target genes OPN, MMP9 and MMP13
(Fig. 2b). Activation of CBFβ also rescued the migration
defect, as determined by a significant increase in the capa-
city of the cells to invade Matrigel and migrate in a wound-
healing assay in the presence of 4OH-T (Fig. 2c). Micro-
scopic analysis of the cells in 3D culture, in the presence
and absence of 4OH-T, revealed a remarkable difference in
phenotypes. In the absence of 4OH-T the cells formed
clusters as expected (Fig. 2d, upper panel). However, cells
grown in the presence of 4OH-T had spread throughout the
culture and were indistinguishable from the parental MDA-
MB-231 cells (Fig. 2d and see Fig. S3 for controls). Fur-
thermore, activation of CBFβ induced an increase in
expression of mesenchymal markers and a decrease in
epithelial markers (Fig. 2e). Consistent with this, we
observed an increase in the number of mammospheres
formed following culture with 4OH-T (Fig. 2f). To
demonstrate that CBFβ can dynamically regulate the plas-
ticity of the cells we added 4OH-T to MDA-CBFβ-ER cells
that had already formed clusters in 3D culture (Fig. 2g). In
the absence of 4OH-T the clusters continued to grow with
little dispersion. In contrast, after three days in the presence
of 4OH-T branched structures were observed, and after
6 days cells were clearly dispersing (Fig. 2g). These data
show that CBFβ drives the mesenchymal phenotype of
MDA-MB-231 and that the EMT/MET state-transition can
be dynamically regulated in metastatic cells by CBFβ.
Depletion of RUNX1 and RUNX2 induces MET
Since both RUNX1 and RUNX2 are expressed in MDA-
MB-231 cells, we sought to establish if a double knock-
down of RUNX1 and RUNX2 phenocopied the effect of
CBFβ-knockdown. We therefore generated cell lines in
which either RUNX1 or RUNX2 were depleted and a cell
line in which both proteins were depleted (Figs. 3a, S4A
and S5A). All three cell lines displayed a significant
decrease in migration and invasion capacity (Figs. 3b, c, S4
and S5) as well as a decrease in mammosphere formation
(Figs. 3d, S4 and S5). Mesenchymal and epithelial marker
expression confirmed that each of the knockdown cell lines
had undergone MET (Figs. 3e, S4 and S5). All of the lines
formed clusters in 3D culture (Figs. 3f, S4 and S5). In
addition, we observed acini-like structures in the double
knockdown cells demonstrating that depletion of both
proteins does indeed phenocopy the effect of CBFβ loss
(Fig. 3f). We did not observe acini in the single knockdown
cell lines, although acini-like structures have previously
been reported in RUNX2-knockdown cells [22]. Taken
together, these findings demonstrate that CBFβ, RUNX1
and RUNX2 are necessary for the maintenance of the
mesenchymal phenotype in MDA-MB-231 cells.
RUNX/CBFβ drives Slug expression to maintain EMT
The EMT transcription factor Slug is encoded by the SNAI2
gene whose expression is reduced in CBFβ, RUNX1 and
Fig. 1 CBFβ maintains the mesenchymal phenotype of metastatic
breast cancer cells. a CBFβ loss results in phenotypic changes. (i)
Western blot shows knockdown of CBFβ in MDA-MB-231 cells,
MDA-shNS and MDA-shCBFβ. The two CBFβ bands likely corre-
spond to the two isoforms known to form complexes with RUNX
proteins, CBFβ (p22) and CBFβ (p21.5). It is likely that the two bands
correspond to these isoforms as they have similar molecular weights.
β-Tubulin was used as a loading control. (ii) Fluorescent microscopy
comparing the shape of GFP-expressing MDA-MB-231 cells and
CBFβ-depleted cells (MDA-shCBFβ). (iii) Following scratch of a
monolayer, live images were taken every 20 min for 48 h. Graph
shows significant reduction in cell mobility in the absence of CBFβ.
Statistical analysis performed using ANOVA. b Loss of CBFβ results
in cluster formation in 3D culture. MDA-MB-231, MDA-shNS and
MDA-shCBFβ were grown in 3D Matrigel for 14 days. GFP (green)
was stably expressed in all cell lines. Cells were fixed and nuclei
stained with DAPI (blue). The wild-type and MDA-shNS cells showed
a stellate mesenchymal growth pattern whilst MDA-shCBFβ cells
formed discrete clusters. Scale bars are 200 μm in the top three rows
and 50 μm in row four. (c) Confocal microscopy showing different
sizes of clusters in the MDA-shCBFβ cells. The lower panels clearly
show a smaller cluster that resembles an acinus. Scale bars are 25 μm.
d Z-stack analysis showing that some smaller clusters contain lumen
and some do not. Scale bars are 50 μm. e Acini express polarity
markers. Immunofluorescence microscopy of MDA-shNS and MDA-
shCBFβ cells in 3D Matrigel after 14 days. Cells were fixed and
stained for apical or basement markers including phospho-Ezrin/
Radixin/Moesin (pERM) and Integrins (Red) and nuclei were stained
with DAPI (Blue). Scale bars are 50 μm. f Loss of CBFβ causes a
reduction in mesenchymal markers and increased expression of epi-
thelial markers. qRT-PCR was performed for epithelial and
mesenchymal markers in MDA-shNS or MDA-shCBFβ from cells
grown in 2D culture. g Loss of CBFβ causes a reduction in the number
of mammosphere-forming colonies. Mammospheres were counted
after 5 days growth in non-adherent culture.
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RUNX2-knockdown cell lines (Figs. 1f, S4 and S5)
[16, 18]. To confirm that the changes in SNAI2 mRNA
expression correlated with Slug protein expression we used
western blotting to determine Slug expression in the MDA-
CBFβ-ER cell line in the presence and absence of 4OH-T
(Fig. 4a). In the absence of 4OH-T Slug expression was
significantly reduced whereas addition of 4OH-T resulted in
a clear increase in expression (Fig. 4a). This suggested that
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the reduction in Slug expression in CBFβ-depleted cells
contributes to the loss of the observed EMT. To test this, we
predicted that re-expression of Slug should rescue the
migration phenotype of CBFβ-depleted cells. We therefore
generated a cell line stably expressing Slug in the
CBFβ-depleted cells. Analysis of these cells in the wound-
healing assay revealed that their ability to migrate had
significantly recovered (Fig. 4b). Moreover, these cells
exhibited a stellate phenotype reminiscent of the wild-type
MDA-MB-231 cells, when grown in 3D culture (Fig. 4c,
lower panels). Furthermore, Slug was depleted in the
RUNX1/2-knockdown cell line and their migratory phe-
notype was rescued by the ectopic expression of Slug (Fig.
4d). ChIP analysis of the SNAI2 promoter clearly demon-
strated that both RUNX1 and RUNX2 could immunopre-
cipitate the promoter but not a control sequence 1.5 kb
upstream (Fig. 4e). Binding to the promoter was abrogated
in RUNX1 and RUNX2-depleted cells (Fig. 4e). Taken
together, these data demonstrate that the RUNX/CBFβ
complexes maintain the mesenchymal phenotype of MDA-
MB-231 cells, at least in part, by regulating the expression
of the EMT transcription factor Slug.
CBFβ contributes to the development of bone
metastasis in mice
To investigate the metastatic potential of the CBFβ-depleted
cells, we first determined their tumourigenic capacity by
direct transplant into the mammary fat pad of mice (Fig. 5a)
[28]. Numbers of tumours in both control and
CBFβ-depleted cells were similar, however tumour volume
in the CBFβ-depleted cells was significantly less than the
shNS cells (Fig. 5a). This correlated with the slower growth
rate of these cells observed in 3D culture (Fig. 5b). To
determine if the MET induction caused by the loss of CBFβ
affected the ability of cells to invade a metastatic niche we
first compared the growth of parental MDA-MB-231 cells
with the CBFβ-depleted cells in co-cultures with osteoblasts
which had been growing for 12 weeks in 3D (Fig. 5c) [29].
Eight days after adding the cells to the osteoblast cultures,
the GFP-expressing parental cells had invaded throughout
the culture, whereas the CBFβ-depleted cells formed dis-
crete clusters and did not permeate the osteoblast network
(Fig. 5c). Having established that the CBFβ-depleted cells
retain the ability to form localised tumours but have a
restricted capacity to grow in osteoblast culture, we next
tested their ability to establish bone metastases after injec-
tion into the circulation by intracardiac injection (Fig. 5d)
[30]. Initial experiments with the CBFβ-depleted cells
resulted in bone tumours in which CBFβ-expression had
recovered from the shRNA (data not shown). This obser-
vation suggested that CBFβ was indeed required for bone
metastases to form. We therefore created a CBFβ-depleted
cell line using CRISPR-Cas9 (Figs. 5d, S6) [31]. These
CBFβ−/− cells showed the same loss of mesenchymal
phenotype, decreased invasion, mammosphere formation
and mesenchymal markers as seen in the shCBFβ cells (Fig.
S6). Intracardiac injection of the CBFβ-CRISPR cells into
mice resulted in a striking reduction of the number of mice
developing bone tumours compared with controls (Fig. 5d).
We found that 7 out of 11 animals injected with the control
cells developed tumours in the hind limbs, with numerous
cancer-induced bone lesions detected, compared with three
out of seven animals injected with CBFβ-CRISPR (Fig. 5d).
In addition, the animals receiving the control cells had
higher numbers of skeletal lesions (average= 8.1 lesions/
mouse) compared with those receiving CBFβ-CRISPR cells
(average= 1.7 lesions/mouse), (Fig. 5d). These data
demonstrate that loss of CBFβ reduces the ability of MDA-
MB-231 cells to metastasise to bone.
Discussion
In this study, we have shown that the RUNX co-regulator
CBFβ is essential to drive MDA-MB-231 breast cancer cells
Fig. 2 CBFβ regulates EMT/MET state-transition. a Inducible
activation of CBFβ. Western blots showing nuclear and cytoplasmic
extracts from 4OH-T and ethanol treated MDA-CBFβ-ER cells using
anti-CBFβ antibody. Lamin B1 and Tubulin were used as nuclear and
cytoplasmic loading controls, respectively. b RUNX-target genes are
activated in MDA-CBFβ-ER cell lines by 4OH-T. Total RNAs were
used to analyse the mRNA levels of known RUNX-target genes, OPN
(osteopontin), MMP9 (matrix metallopeptidase-9) and MMP-13
(matrix metallopeptidase-13). c Activation of CBFβ-ER with 4OH-T
restores cell invasion and mobility capacity. (i) Matrigel invasion assay
showing the recovery of invasion in the presence of 4OH-T following
24 h culture. (ii) Following scratch of a monolayer, live images were
taken every 20 min for 48 h. Graph shows migration capacity is
restored in the presence of 4OH-T in CBFβ-ER cells. Statistical ana-
lysis performed using ANOVA. d Induction of CBFβ-ER with 4OH-T
restores the mesenchymal phenotype in 3D culture. The GFP-
expressing cells were visualised by fluorescence microscopy and
DAPI staining. The upper panel shows MDA-CBFβ-ER cells grown
after addition of vehicle (ethanol). The lower panel shows 4OH-T
treated MDA-CBFβ-ER cells. Scale bars are 200 μm in the large image
and 50 μm in the inset image. e Re-expression of CBFβ restores EMT
marker gene expression. Epithelial and mesenchymal marker genes
were analysed by qRT-PCR on RNA isolated from MDA-CBFβ-ER
cells grown in the presence 4OH-T or ethanol. f Induction of
CBFβ-ER restores mammosphere formation capacity. MDA-CBFβ-ER
and control MDA-pcDNA3.1/H cells were grown with 4OH-T or
ethanol and their mammopshere forming capacity subsequently
determined. Mammospheres were counted after 5 days growth in non-
adherent culture. g Immunofluorescence microscopy of MDA-
CBFβ-ER cells in 3D culture showing dispersion of cell clusters upon
activation of CBFβ. Cells were grown in Matrigel for 8 days (day 0 of
4OH-T addition), prior to addition of 4OH-T or ethanol. Cells were
fixed and visualised for GFP (green) and DAPI (blue). Scale bars are
200 μm.
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through EMT. Maintenance of the mesenchymal phenotype
is, at least in part, achieved by regulating the expression of
the EMT transcription factor Slug. We also demonstrated
that the MET induced by loss of CBFβ is completely
reversible by re-expression of CBFβ. These findings are
important since they demonstrate that, in principle,
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regulation of RUNX/CBFβ activity can determine the extent
to which triple-negative breast cancer cells differentiate
along the epithelial-mesenchymal continuum. In the context
of metastasis in vivo this raises the possibility that inter-
actions between cancer cells and the microenvironment
influence the activity of RUNX/CBFβ, thereby shifting their
phenotype toward the epithelial state and enabling the cells
to colonise the new niche. Indeed, the loss of CBFβ sig-
nificantly reduced the capacity of metastatic cancer cells to
invade osteoblast cultures in vitro and to form osteolytic
lesions in vivo.
Previous work has shown that about two thirds of the
RUNX1 transcriptome is shared with the RUNX2 tran-
scriptome in MCF7 cells [19]. Our finding that CBFβ,
RUNX1 and RUNX2 are all necessary for SNAI2 expres-
sion suggests that all three factors combine to ensure a
sufficient level of Slug is available to maintain the
mesenchymal phenotype. This suggests that none of these
factors are redundant in this context. This may reflect the
need for a threshold level of RUNX factors to be expressed
but does not discount the possibility that RUNX1 and
RUNX2 also regulate specific subsets of genes. SNAI2 is a
well-established EMT transcription factor that appears to be
a key target for RUNX transcription factor complexes and is
perhaps one of several genes that contribute to the meta-
static nature of breast cancer cells [16, 18].
In contrast to these findings, we did not observe sig-
nificant changes in classical EMT markers when either
CBFβ or RUNX1 was depleted in MDA-MB-468 cells. The
emerging picture is that RUNX complexes have pleiotropic
effects dependent on the cellular context and it is of note
that whilst MDA-MB-231 and MDA-MB-468 cells are both
“triple-negative” they exhibit different characteristics and
gene expression profiles, MDA-MB-231 being of the
claudin low sub-type and MDA-MB-468 are basal [32].
Moreover, mutations in RUNX1 and CBFβ are associated
with the ER+ sub-type of breast cancer and is therefore
predicted to have a tumour suppressor role in this context
[7, 8, 33]. Indeed, previous studies have shown that
RUNX1 suppresses development of ER+ luminal breast
cancer but it is not known how CBFβ contributes in this
context [34]. Our finding that depletion of RUNX1 in
MDA-MB-231 cells induces MET is in agreement with a
previous study in which the expression of miR-378 in
MDA-MB-231 cells, which inhibits RUNX1 expression,
also resulted in suppression of migration and invasion [35].
However, this is in contrast to the role of RUNX1 in
MCF10A and MCF7 cells where RUNX1 expression is
required to maintain an epithelial-like phenotype [20, 36].
Taken together these findings suggest that RUNX tran-
scription factors contribute to the epithelial-mesenchymal
continuum is a cell-context dependent manner.
Finally, small molecule inhibitors that inhibit the inter-
action between CBFβ and RUNX have been shown to
inhibit colony formation in a basal-like breast cancer cell
line [37]. Our findings that CBFβ is essential to maintain the
mesenchymal phenotype, and that it contributes to the for-
mation of bone metastases, suggests that in principle inhi-
biting this complex might maintain metastatic colonies in a
less aggressive epithelial state by driving MET. Thus, tar-
geting the RUNX/CBFβ complex in this way might be a
viable option to treat a sub-group of triple-negative breast
cancer patients.
Methods
Cell lines
Parental MDA-MB-231 expressing GFP were a kind gift from
D. Welch, University of Alabama. MDA-MB-231-shCBFβ/
RUNX1/RUNX2 were produced using Sure Silencing shRNA
plasmids (SABiosciences) as previously described [16]. Lines
were authenticated by multiplex-PCR assay using the AmpF/
STR system (Applied Biosystems) and confirmed as myco-
plasma free. Monolayers were grown in complete medium
(DMEM/10% FCS/2mmol/L L-glutamine/PenStrep 0.4 μg/mL
puromycin, 50 μg/mL geneticin, 500 μg/mL hygromycin as
required) and maintained in a humidified incubator at 37 °C at
an atmospheric pressure of 5% (v/v) CO2/air.
Western blotting
Protein was separated on an SDS–PAGE and transferred to
Hybond-C Extra nitrocellulose membrane. Primary anti-
bodies included: β-Tubulin (Abcam, ab6046), Lamin-B1
(Abcam, ab16048), CBFβ (Abcam, ab33516), RUNX1
(Abcam, ab23980), RUNX2 (MBL, D130-3), Snai2 (Cell
Signalling, C19G7), FLAG (Sigma, F1804).
Fig. 3 Knockdown of RUNX1 and RUNX2 induces MET. a qRT-
PCR showing knockdown of RUNX1 and RUNX2 by shRNA. Total
RNAs were used to analyse the mRNA levels of RUNX1 and RUNX2.
RPLO mRNA was used as a control for normalisation and relative
values are shown. b Scratch assays showing inhibition of migration in
MDA-shRUNX2-shRUNX1 cells. Following scratch of a monolayer,
live images were taken every 20 min for 48 h. Graph shows significant
reduction in cell mobility in the absence of RUNX1/RUNX2. c
Matrigel invasion assay showing inhibition of migration in MDA-
shRUNX2-shRUNX1 cells. d Loss of RUNX1 and RUNX2 causes a
reduction in mammosphere formation. Mammospheres were counted
after 5 days growth in non-adherent culture. e Loss of RUNX1 and
RUNX2 in MDA-MB-231 cells causes a reduction in mesenchymal
markers and increased expression of epithelial markers as seen by RT-
PCR. f Loss of RUNX1 and RUNX2 results in cluster formation in 3D
culture. Immunofluorescence microscopy of MDA-MB-231 and
MDA-shRUNX2-shRUNX1 cells in Matrigel after 14 days growth.
The confocal images show equatorial cross sections. Scale bars are
50 μm.
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For all experiments three biological replicates were per-
formed and densitometry was conducted to calculate aver-
age changes using ImageJ software, which is freely
available at http://rsb.info.nih.gov/ij/.
Cell scratch assay
Confluent monolayers were scratched on day 0 and med-
ium was changed to serum free. Cells were grown in an AS
MDW live cell imaging microscope system at 37 °C 5%
CO2 for 48 h. Images were taken every 20 min and 40
views were taken in each well. For all experiments three
technical and three biological replicates were performed.
Image data analysis was performed using Cell Profile
software.
Overlay three-dimensional culture of breast cells
Matrigel (Corning, 354230) was thawed on ice overnight
at 4 °C and then spread evenly onto dishes (MatTek P35G-
1.0-14-C) or into 24-well plates (Greiner, Bio-one
662892). Cells were resuspended in 3D assay medium
(2% Matrigel, 95% DMED, 2%FBS, 1% Pen/Strep, 1%
nonessential amino acid, 1% L-glutamine) and plated on to
solidified Matrigel. Cells were grown in 5% CO2 humi-
dified incubator at 37 °C. Assay medium was changed
every 3 or 4 days. Cells were fixed at day 14. For all
experiments three technical and three biological replicates
were performed.
Microscopy
2D culture
Images were collected on a Zeiss Axioimager.D2 upright
microscope using a 10× objective and captured using a
Coolsnap HQ2 camera (Photometrics) through Micro-
manager software v1.4.23. Specific band pass filter sets for
DAPI, FITC and Cy5 were used to prevent bleed through
from one channel to the next.
3D culture
Images were collected on a Leica TCS SP5 AOBS inverted
and upright confocal microscopes. Images were collected
using PMT detectors with the following detection mirror
settings; [FITC 494–530 nm; Texas red 602-665 nm; Cy5
640-690 nm] using the [488 nm (20%), 594 nm (100%) and
633 nm (100%)] laser lines, respectively. When it was not
possible to eliminate cross-talk between channels, the
images were collected sequentially. When acquiring 3D
optical stacks the confocal software was used to determine
the optimal number of Z sections. Only the maximum
intensity projections of these 3D stacks are shown in the
results. Images were then processed and analysed using Fiji
ImageJ (http://imagej.net/Fiji/Downloads) [14], which is
freely available online.
For all experiments three technical and three biological
replicates were performed.
Immunofluorescence
For cell grown on coverslips, fixing and permeabilisation
was performed in 4% paraformaldehyde (Sigma) and
0.1% Triton-100 (Sigma) before blocking in 1% Bovine
Serum Albumin. The cells were then incubated with the
primary antibodies overnight at 4 °C at a dilution of
10 µg/µl). pERM (Cell Signalling Technology; Antibody
#3141), anti-integrin avβ6 (Abcam, ab97588). Alexa-
fluor secondary antibodies (Invitrogen) were used at a
1/200 dilution. The coverslips were mounted on glass
slides using mounting medium with DAPI (Invitrogen
P36965). For cells grown in Matrigel, following fixing
and permeabilisation as detailed above non-specific
staining was blocked using cells were blocked using IF
Buffer (7.7 mM NaN3, 0.1% bovine serum albumin,
0.2% Triton X-100, 0.05% Tween-20 in PBS)+ 10%
goat serum. Cells were stained using Phalloidin for
F-actin (Sigma, P1951) and mounted using DAPI
(Invitrogen).
For all experiments three technical and three biological
replicates were performed.
Fig. 4 RUNX/CBFβ maintains EMT via the EMT transcription
factor Slug. a Activation of CBFβ restores expression of Slug in
MDA-CBFβ-ER cells. Western blot for CBFβ and Slug performed on
cell lysates from MDA-MB-231, MDA-shCBFβ, MDA-shNS, MDA-
CBFβ-ER and MDA-pcDNA3.1/H cells in the presence and absence
of 4OH-T. Tubulin was used as the loading control. b Slug expression
in MDA-shCBFβ cells partially restores cell migration capacity.
Wound-healing assay showing the recovery of migration capacity in
cell depleted of CBFβ and cells stably expressing Slug. Following
scratch of a monolayer, live images were taken every 20 min for 48 h.
c Re-expression of Slug induces a mesenchymal spreading phenotype
in MDA-shCBFβ cells in 3D culture. Scale bars are 50 μm.
d Expression of Slug in RUNX-depleted cells restores their invasive
capacity. Cells were transfected with a Slug-Myc expressing plasmid
or the control plasmid pcDNA3.1/Hygro. Western analysis shows
expression of exogenous Slug-Myc. Expression of endogenous Slug
(lower band in the Slug panel) and exogenous Slug-Myc (upper band
in the Slug panel) was analysed by western blot from total cell lysates
72 h after transfection. The Graph shows Matrigel invasion assays of
transiently transfected Slug-Myc-expressing cells. Invasion was
restored in all three knockdown cells (from left to right, MDA-shNS,
MDA-shCBFβ, MDA-shRunx2, MDA-shRunx2-shRunx1 cells).
e ChIP assay showing binding of RUNX1 and RUNX2 to the SNAI2
promoter. Percentage input of RUNX protein binding is shown relative
to the anti-rabbit IgG antibody.
R. Ran et al.
Mammosphere culture
Mammosphere culture was carried out as previously
described [38]. Spheres >50 µm were counted on day 5. For
all experiments three technical and three biological repli-
cates were performed.
Quantitative reverse transcription PCR
RNA was extracted using the Qiagen RNAeasy kit
according to manufacturer’s instructions and quantified on
the Nanodrop spectrophotometer (Thermo). Real time one
step qRT-PCR was carried out using the QuantiTect
SYBR® Green RT-PCR Kit (Qiagen) according to manu-
facturer’s instructions before analysis on the 7900 PCR
machine (Applied Biosystems). A table of the primers used
can be found in Supplementary Table 1. For all experiments
three biological replicates were performed.
Inducible Cell line production
Mouse CBFβ-FLAG and ER was ligated into pcDNA3.1/
Hygro(-) vector producing pcDNA3.1/Hygro(-)-CBFβ-FLAG-
ER. Stable lines were made using this vector and cells were
Fig. 5 CBFβ contributes to the
development of bone
metastasis. a MDA-MB-231
cells were transplanted into the
inguinal mammary fat pad of
CD1-Nude females. Data shown
at 4 weeks post-transplantation.
Data is presented as mean ±
SDM (shNS; n= 5; shCBFβ;
n= 7). The difference between
the two groups is significant
(p < 0.05) as determined using
an unpaired Student’s t-test. b
Growth curves showing
knockdown of CBFβ reduces
growth rate in 3D culture.
MDA-MB-231, MDA-shNS, or
MDA-shCBFβ cells were grown
on 3D culture and cells were
counted every 2 days. c
Knockdown of CBFβ inhibits
invasion in 3D co-cultures with
osteoblasts. 3D cultures of MC-
3T3 osteoblasts were grown for
2 months prior to addition of
MDA-MB-231 or MDA-
shCBFβ cells. Confocal images
were taken after 8 days of co-
culture. Cells were stained with
phalloidin. MDA cells were
identified by GFP fluorescence. d
CBFβ silencing reduces tumour
growth in bone in vivo. MDA-
MB-231 control or CBFβ−/−
cells were injected i.c. into 6-
week old BALB/c nude mice and
tumour growth in the hind limbs
analysed 26 days later. 3D
reconstruction of tumour-bearing
tibia showing the presence of
osteolytic lesions. The histogram
shows the average number of
bone tumours per mouse for each
cell line as indicated.
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transfected using Lipofectamine according to manufacturer’s
instructions (Fig. S1).
Nuclear/Cytoplasmic separation
Cells were resuspended in 400 μl of ice cold Buffer A
(10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF) with the
addition of complete mini-EDTA-free protease inhibitor
cocktail (Roche) and incubated at 4 °C for 15 min. Cells
were lysed by addition of 10% NP-40 (Sigma) before
centrifuging at 4 °C and removal of the cytoplasmic extracts
in the supernatant. The pellet was then resuspended in ice
cold Buffer B (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT and 1 mM PMSF) con-
taining protease inhibitors and vortexed vigorously for
45 min at 4 °C. Nuclear proteins were collected from
supernatant following centrifugation at 4 °C. For all
experiments three biological replicates were performed.
Invasion assay
Matrigel Matrix (Corning, 354230) was diluted to final
concentration of 300 μg/mL in cold coating buffer (0.01 M
Tris (pH8.0), 0.7% NaCl) before being added to invasion
chambers (Corning Cat, 353097) and left to set overnight at
37 °C. 2 × 104 cells were added to each chamber in serum
free medium and 0.75 mL complete medium was added to
the wells. Cells were allowed to invade 24 h in cell culture
incubator. Invading cells were fixed and permeabilised with
4% PFA (Electron Microscopy Sciences, 15713-S) and
0.1% Triton (Sigma). Non-Invading cells were removed
using a cotton swab. Cells were stained with Crystal violet
solution. For all experiments three technical and three bio-
logical replicates were performed.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described [39]. ChIP-PCR
was performed using Quantitect SYBR green (Qiagen). The
primers used can be found in Supplementary Table 1. For all
experiments three biological replicates were performed.
CRIPSR-Cas9 mediated gene deletion
CBFβ and RUNX1 gene knockout was performed using a
double nickase CRISPR-Cas9 strategy as described pre-
viously [31]. Guide-RNA sequences were designed using
E-CRISP to minimise off target effects [24]. Cells were
Fluorescence-activated cell sorted (FACS) for GFP-Cas9
expression 48 h after transfection and grown up from single
colonies prior to genomic DNA PCR and western blot
screening.
Mammary fat pad xenografts
3 × 106 MDA-MB-231 cells were transplanted in matrigel
into the inguinal mammary fat pad of 12 week old CD1-
Nude females (Charles River, UK). Mice were randomised
to receive shNS or shCBFβ-KO cells to give groups of
comparable weight/age. The same investigator (SMM)
transplanted all cells into the recipients.
Animals were excluded if they failed to grow a tumour to
clinical endpoint, and/or exhibited unrelated general ill
health within the duration of the experiment.
Caliper measurements were carried out throughout by
technical staff blinded to the expected outcome of the
experiment to assess tumour volume which was calculated
using the formula ½(length × width2).
This experiment was carried out in dedicated animal
facilities under project licence 60/4181 with adherence to
the Animal (Scientific Procedures) Act, the European
Directive 2010 and local ethical approval (University of
Glasgow). No randomisation was required.
Bone tumour growth studies
Tumour growth studies used 6–8 week old female BALB/c
nude between 13 and 18.4 g (Charles River, Kent, UK).
Experiments were carried out in accordance with local
guidelines and with Home Office approval under project
licence 70/8799, University of Sheffield, UK. 12 mice per
group were injected with 1 × 105 MDA-MB-231 control
(2014-8-044) or CBFβ-CRISPR knockout cells (2015-6-
010 CRISPR) via the left cardiac ventricle to generate
tumours in bone [30]. Mice were randomised to receive
control or CBFβ-KO cells to give groups of comparable
weight/age. Mice were removed early from the study if they
showed luciferase signal in the chest only (indicating a
missed injection) or if the mice developed hind limb
paralysis within the first 48 h. These parameters were pre-
defined before the experiment commenced.
Animals were culled 26 days following tumour cell
injection and hind limbs collected for analyses of tumour
growth and associated bone lesions in tibiae and femurs.
Analysis of bone lesions
Hind limbs were fixed in 4%PFA and scanned by μCT prior
to decalcification in 1%PFA/0.5% EDTA and processing
for histological sectioning. μCT analysis was carried out
using a Skyscan 1272 × -ray-computed μCT scanner (Sky-
scan, Aartselar, Belgium) equipped with an x-ray tube
(voltage, 50 kV; current, 200uA) and a 0.5-mm aluminium
filter. Pixel size was set to 5.99 μm and scanning initiated
from the top of the proximal tibia or distal femur. Lytic,
tumour-induced bone lesions were counted manually for
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each bone and performed by a technician being unaware of
anticipated outcome of the experiment.
Statistical analysis
Data is represented as mean+/− SD, n= 3 unless other-
wise stated.
Statistical significance was measured using parametric
testing, assuming equal variance, unless otherwise stated,
with standard t-tests for two paired samples used to assess
difference between test and control samples. An asterisk (*)
indicates 0.01 < P < 0.05; ** indicates 0.001 < P < 0.01; ***
indicates P < 0.001; **** indicates P < 0.0001; N indicates
0.05 < P when compared to control.
Power calculations were performed for mammary fat pad
experiments. Using 80% power and 95% confidence, 25%
practical difference and 15% coefficient of variation we
anticipated that 8-10 mice was required for each cohort and
so n= 10 animals per cohort were transplanted.
Power calculations were also performed for bone tumour
growth assays based on the minimum number of animals
required to obtain statistically significant data in a factorial
ANOVA design were based on our extensive previous
studies: Metastasis is known to develop in the hind limbs of
80–90% of mice injected with control MDA-MB-231 cells,
for studies predicted to decrease metastasis (or metastatic
lesions) by 70%, a minimum of six mice per group is
required to obtain 80% power with 10% error.
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